

Ref: FOIA Reference 2024/25-545

Royal Stoke University Hospital
Data, Security and Protection
Newcastle Road
Stoke-on-Trent
Staffordshire
ST4 6QG

Date: 6th December 2024

Email foi@uhnm.nhs.uk

Dear Sir/ Madam

I am writing to acknowledge receipt of your email dated 8th November 2024 requesting information under the Freedom of Information Act (2000): Endometrial Cancer

Q1 I am researching the incidence and treatment of Endometrial Cancer. I would greatly appreciate if you could answer the following questions.

Does your Trust provide SACT (systemic anti-cancer therapy) treatments for endometrial cancer? If not, which other Trust do you refer endometrial cancer patients to for SACT treatments?

A1 Yes

Q2 How many patients were treated for endometrial cancer (any stage) in the past three months with the following treatments:

- Dostarlimab (Jemperli)
- Dostarlimab (Jemperli) AND Chemotherapy
- Hormone therapy (Progesterone or Letrozole)
- Pembrolizumab (Keytruda) monotherapy
- Lenvatinib + Pembrolizumab (Lenvima +Keytruda)
- Platinum-based chemotherapy (monotherapy or combination with taxanes, anthracyclines, cyclophosphamide)
- Any other SACT
- Any other Chemotherapy

A2 We are unable to provide the information you require in the requested format as to release this data could lead to the identification of the person(s) involved due to the low numbers involved and would breach the Trusts obligations under Data Protection Act 2018. Accordingly, this aspect of your request is exempt from disclosure under the terms of Section 40(2) of the FOI Act. *Personal information*. However, as the Trust is committed to openness and transparency we can band the numbers as being <5
This exemption is an absolute exemption and therefore no consideration of the public interest test is needed.

Dostarlimab (Jemperli)	<5
Dostarlimab (Jemperli) AND Chemotherapy	<5
Hormone therapy (Progesterone or Letrozole)	Info Not Recorded at UHNM
Pembrolizumab (Keytruda) monotherapy	0
Lenvatinib + Pembrolizumab (Lenvima +Keytruda)	<5
Platinum-based chemotherapy (monotherapy or combination with taxanes, anthracyclines, cyclophosphamide)	14
Any other SACT	<5
Any other Chemotherapy	0

Q3 In the past three months, how many patients were treated for recurrent endometrial cancer after having previously received platinum-based chemotherapy?

A3 Five

Q4 In the past three months, how many patients were treated for endometrial cancer with the following as first line treatments:

- Dostarlimab (Jemperli) AND Chemotherapy
- Hormone therapy (Progesterone or Letrozole)
- Platinum-based chemotherapy (monotherapy or combination with taxanes, anthracyclines, cyclophosphamide)
- Any other SACT
- Any other chemotherapy

A4 We are unable to provide the information you require in the requested format as to release this data could lead to the identification of the person(s) involved due to the low numbers involved and would breach the Trusts obligations under Data Protection Act 2018. Accordingly, this aspect of your request is exempt from disclosure under the terms of Section 40(2) of the FOI Act. *Personal information*. However, as the Trust is committed to openness and transparency we can band the numbers as being <5
This exemption is an absolute exemption and therefore no consideration of the public interest test is needed.

Dostarlimab (Jemperli) AND Chemotherapy -	<5
Hormone therapy (Progesterone or Letrozole)	Info Not Recorded at UHNM
Platinum-based chemotherapy (monotherapy or combination with taxanes, anthracyclines, cyclophosphamide)	14
Any other SACT	0
Any other chemotherapy	0

Q5 Does your Trust participate in any clinical trials for the treatment of endometrial cancer? If so, can you please provide the name of each trial and the number of patients taking part.

A5 No

*Please note that any individuals identified do not give consent for their personal data to be processed for the purposes of direct marketing.

UHNM NHS Trust is a public sector body and governed by EU law. FOI requestors should note that any new Trust requirements over the EU threshold will be subject to these regulations and will be advertised for open competition accordingly.

Where the Trust owns the copyright in information provided, you may re-use the information in line with the conditions set out in the Open Government Licence v3 which is available at <http://www.nationalarchives.gov.uk/doc/open-government-licence/version/3/>. Where information was created by third parties, you should contact them directly for permission to re-use the information.

An anonymised copy of this request can be found on the Trust's disclosure log, please note that all requests can be found at the following link: <http://www.uhnm.nhs.uk/aboutus/Statutory-Policies-and-Procedures/Pages/Freedom-of-Information-Disclosure-Log.aspx>

This letter confirms the completion of this request. A log of this request and a copy of this letter will be held by the Trust.

If you have any queries related to the response provided please in the first instance contact my office.

Should you have a complaint about the response or the handling of your request, please also contact my office to request a review of this. If having exhausted the Trust's FOIA complaints process you are still not satisfied, you are entitled to approach the Information Commissioner's Office (ICO) and request an assessment of the manner in which the Trust has managed your request.

The Information Commissioner may be contacted at:

Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire SK9 5AF or via www.ico.org.uk.

Yours,



Leah Carlisle
Head of Data, Security & Protection and Health Records
Data Protection Officer